Release Summary

IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs. Data presented today at Keystone Tumor Immunology Symposium, Banff.

IOmet Pharma